Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22454243 | 0.80 | PDE10A (0.43) | MEN1LMNAKMT2APANK3SMN1; SMN2 | |
| SCHEMBL26501718 | 0.79 | PANK3 (0.35) | MEN1LMNAKMT2APANK3 | |
| SCHEMBL26501678 | 0.79 | PANK3 (0.42) | MEN1LMNAKMT2APANK3TSHR | |
| SCHEMBL26501648 | 0.78 | DHFR (0.47) | MEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL18500836 | 0.77 | TSHR (0.31) | TSHRSMN1; SMN2GAA | |
| SCHEMBL22662254 | 0.74 | CYP1A2 (0.55) | LMNATSHRSMN1; SMN2 | |
| SCHEMBL5515445 | 0.73 | SMN1; SMN2 (0.41) | MEN1LMNAKMT2APANK3TSHR | |
| SCHEMBL20932917 | 0.72 | ESR1 (0.39) | MEN1LMNAKMT2APANK3TSHR | |
| SCHEMBL27779353 | 0.72 | ESR1 (0.39) | MEN1LMNAKMT2APANK3TSHR | |
| SCHEMBL12185864 | 0.72 | ESR1 (0.42) | MEN1LMNAKMT2APANK3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | MEN1 2263/4885LMNA 1621/4885KMT2A 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.